Clinical Trial Update: Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma [Phase 4]

View source ↗

Summary

Phase 4 trial update showing completion of two bortezomib-based regimens (VAMP/TaCyDex and V-MP/TaCyDex) in refractory or relapsed multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Doxorubicin (doxorubicin)
• Melphalan (Melphalan)
• PREDNISONE (Prednisone)
• Thalidomide (thalidomide)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Multiple Myeloma | Phase 4 | Status: COMPLETED